Related Experiment Video
Updated: Apr 25, 2026
Optimization of High Grade Glioma Cell Culture from Surgical Specimens for Use in Clinically Relevant Animal Models and 3D Immunochemistry
Published on: January 7, 2014
Variability of the Immunosuppressive Properties of Glioma Cell Lines
I V Kholodenko1, R Yu Saryglar2, A Y Lupatov2
1Institute of Biomedical Chemistry, Moscow, Russia. irkhol@yandex.ru.
Abstract:
Immunotherapeutic methods, such as the use of checkpoint inhibitors, CAR T cells, dendritic cell vaccines, etc., offer promising approach to the treatment of glioblastomas. Dendritic cell (DC)-based vaccines used in glioma therapy have been well studied and are effective in some cases. However, the use of DC vaccines for the treatment of patients with gliomas, though shows promising results, is still limited by the suboptimal choice of tumor antigen and the method of its loading, as well as the immunosuppressive nature of the tumor cell microenvironment. In this work, we showed that glioma cell lines express a broad spectrum of immune checkpoints, suppress the maturation of allogeneic DCs during direct co-culturing, and do not stimulate the proliferation of allogeneic lymphocytes. Lymphocytes primed with dendritic cells loaded with the corresponding tumor lysates effectively lysed only two of three glioma cell lines, T98G and U373 MG, whereas 1321N1 cells completely suppressed the cytotoxic activity of lymphocytes primed by co-culturing with DCs loaded with the lysate of these cells. Thus, the efficacy of DC vaccines may be related to the individual characteristics of glioma cells.
Insights
Dendritic cell (DC) vaccines show promise for glioblastoma treatment but face challenges. Their effectiveness depends on individual glioma cell characteristics and the tumor microenvironment, impacting immune responses.
Area of Science:
- Immunotherapy
- Oncology
- Cellular Immunology
Background:
- Dendritic cell (DC)-based vaccines are a promising immunotherapeutic approach for glioma.
- Current limitations include suboptimal antigen selection, loading methods, and the immunosuppressive tumor microenvironment.
- Glioma cells express immune checkpoints and can inhibit DC maturation and lymphocyte proliferation.
Purpose of the Study:
- To investigate the efficacy of DC vaccines against different glioma cell lines.
- To analyze the impact of glioma cell characteristics on DC vaccine effectiveness.
- To understand the interaction between glioma cells, DCs, and lymphocytes in the tumor microenvironment.
Main Methods:
- Co-culturing of glioma cell lines with allogeneic dendritic cells (DCs).
- Assessment of DC maturation and allogeneic lymphocyte proliferation.
- Evaluation of lymphocyte-mediated cytotoxicity against glioma cells after priming with antigen-loaded DCs.
Main Results:
- Glioma cell lines express immune checkpoints and suppress allogeneic DC maturation and lymphocyte proliferation.
- DC vaccines loaded with tumor lysates showed effective lysis of T98G and U373 MG cell lines.
- 1321N1 glioma cells resisted lysis and suppressed cytotoxic activity of primed lymphocytes, indicating cell-specific immune evasion.
Conclusions:
- The efficacy of dendritic cell vaccines in glioma therapy is significantly influenced by individual glioma cell characteristics.
- Understanding glioma cell-specific immune evasion mechanisms is crucial for optimizing DC vaccine design.
- Further research is needed to overcome tumor-induced immunosuppression for effective glioma immunotherapy.
